ONO-2370 a Phase 2 Double-Blind, Randomised, Placebo-Controlled, Parallel-Group study, and an Open-Label, Uncontrolled, Multicenter, Long-term, Extension study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Opicapone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 22 May 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2016 New trial record
- 12 Apr 2016 Status changed from not yet recruiting to recruiting.